Recorlev (levoketoconazole), Strongbridge Biopharma’s oral investigational therapy, lessens disease symptoms and depression, and improves quality of life among people…
Articles by Marta Figueiredo, PhD
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Researchers report a very rare case of Cushing’s disease in a 34-year-old woman caused by a “collision” brain tumor, a…
Using steroid-based creams to treat skin conditions in the genital area may lead to the fast development of medication-related…
Dissolving hydrocortisone tablets in water for multiple daily dosing to treat congenital adrenal hyperplasia (CAH) in children may…
Recordati’s Isturisa (osilodrostat) safely and effectively normalizes urinary levels of cortisol in people with endogenous Cushing’s…
Recognizing discrepancies between blood tests of adenocorticotropic hormone (ACTH) levels and patients’ clinical data is important for clinicians to avoid unnecessary…
Strongbridge Biopharma released additional positive results from a Phase 3 trial evaluating whether the company’s investigational therapy Recorlev (levoketoconazole) is…
Bilateral adrenalectomy, in which the adrenal glands are removed, has a bigger negative impact on the quality of life of…
Recorlev (levoketoconazole) safely and successfully reduces the levels of cortisol in patients with endogenous Cushing’s syndrome, according to top-line…